Table 2 Prediction models for the leiomyosarcoma cohort based on each type of splicing event
Risk score | Model | HR (95% CI) | p-value | ROC |
|---|---|---|---|---|
Risk score (AA) | COPA_8458_AA * (− 0.168) + DMTF1_80302_AA * 0.035 + SNRPN_29704_AA * 0.361 | 3.102 (1.635–5.886) | 0.0005 | 0.745 |
Risk score (AD) | IFT81_24411_AD * 0.053 + NFATC4_26993_AD * (− 0.073) + RMI2_34011_AD * (− 0.092) + TLE3_31418_AD * (− 0.05) | 6.875 (3.363–14.06) | < 0.0001 | 0.763 |
Risk score (AP) | CD2BP2_36095_AP * 0.463 + HMGCL_1078_AP * 0.228 + PAIP1_71959_AP * (− 0.209) + RAB5B_22326_AP * (− 0.175) + VAT1_41179_AP * 0.256 | 2.783 (1.445–5.360) | 0.0022 | 0.86 |
Risk score (AT) | ABCA1_87106_AT * (− 0.429) + C12orf75_24135_AT * 3.806 + COA3_41129_AT * (− 0.334) + TMEM14B_75308_AT * 0.131 | 3.282 (1.743–6.180) | 0.0002 | 0.751 |
Risk score (ES) | EDEM1_63033_ES * (− 0.51) + GNB2L1_75087_ES * (− 0.55) + NSUN5_270163_ES * 0.295 + RAB11FIP3_32895_ES * (− 0.089) + ZMYND11_10590_ES * (− 0.264) | 5.290 (2.704–10.35) | < 0.0001 | 0.857 |
Risk score (RI) | CASP1_18519_RI * (− 0.043) + CCDC107_86266_RI * 0.103 + GBA2_86290_RI * (− 0.047) + KLHL25_32357_RI * (− 1.282) + TKT_65298_RI * (− 0.076) | 6.271 (3.195–12.31) | < 0.0001 | 0.797 |
Risk score (merged) | NFATC4_26993_AD * (− 0.153) + HMGCL_1078_AP * 0.321 + COA3_41129_AT * (− 0.471) + TMEM14B_75308_AT * 0.328 + EDEM1_63033_ES * (− 0.447) + NSUN5_270163_ES * 0.493 + ZMYND11_10590_ES * (− 0.339) | 5.678 (2.946–10.94) | < 0.0001 | 0.781 |